Boothbay Fund Management Increases Stake in CG Oncology

Institutional investor boosts holdings in clinical-stage biotech company

Mar. 17, 2026 at 7:24am

Got story updates? Submit your updates here. ›

Boothbay Fund Management LLC increased its stake in CG Oncology, Inc. (NASDAQ:CGON) by 67.9% during the third quarter, according to a recent SEC filing. The fund now owns 94,479 shares of the company's stock, worth approximately $3.81 million.

Why it matters

CG Oncology is a clinical-stage biopharmaceutical company focused on developing novel antibody-based immunotherapies for solid tumor cancers. Institutional investor activity in the company's stock can signal confidence in the company's pipeline and future prospects.

The details

Boothbay Fund Management purchased an additional 38,224 shares of CG Oncology during the third quarter, bringing its total holdings to 94,479 shares. This represents approximately 0.12% of the company's outstanding shares. CG Oncology is currently developing multiple preclinical programs and early-phase clinical trials for its lead candidates.

  • Boothbay Fund Management increased its stake in CG Oncology during the third quarter of 2026.
  • CG Oncology filed its most recent SEC report in March 2026.

The players

Boothbay Fund Management LLC

An institutional investment firm that manages a portfolio of equity holdings.

CG Oncology, Inc.

A clinical-stage biopharmaceutical company focused on developing novel antibody-based immunotherapies for solid tumor cancers.

Got photos? Submit your photos here. ›

The takeaway

Increased institutional investment in CG Oncology signals growing confidence in the company's pipeline and potential to advance its clinical-stage oncology therapies.